Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

AIMS: Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once‐daily oral drug to treat sickle cell disease (SCD). This first‐in‐human study evaluated the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchaleelaha, Athiwat, Patel, Mira, Washington, Carla, Siu, Vincent, Allen, Elizabeth, Oksenberg, Donna, Gretler, Daniel D., Mant, Timothy, Lehrer‐Graiwer, Josh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533444/
https://www.ncbi.nlm.nih.gov/pubmed/30743314
http://dx.doi.org/10.1111/bcp.13896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533444/
https://www.ncbi.nlm.nih.gov/pubmed/30743314
http://dx.doi.org/10.1111/bcp.13896

Ejemplares similares